Moreno MK, Aragón GM

Language: Spanish
References: 19
Page: 625-630
PDF size: 206.61 Kb.

ABSTRACT

Polycystic Ovary Syndrome is frequent endocrine disease affecting 6-8% women worldwide. It is associated with insulin resistance, hyperandrogenemia and metabolic syndrome, alterations which condition this syndrome to be heterogeneous. Other important pathologies such as ovary and adrenal malignancies can be excluded through proper differential diagnosis, which also allows for an early detection on complications like insulin resistance. This review offers an update with special interest on its physiopathology and diagnosis.

REFERENCES

1. Azzis R, Carmina E, Dewailly D, Diamanti-Kanarakis E, Escobar- Morreale H, Futterweit W, Janssen O, Legro R, Norman R, Taylor A, Witchel S. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report- Fertility and Sterility 2009; 91 (2): 456-488.

2. Balen A, Rajkowha M. Polycystic ovary syndrome-a systemic disorder? Best Pract Res Clin Obstet Gynaecol 2003;17: 263-74.

3. Blumel BE, Flores MA, Gonzáles JA, Arraztoa JA. ¿Es el HOMA un instrumento adecuado para diagnóstico de insulino resistencia en pacientes con SOP? Revista Chilena de Obstetricia y Ginecología. 2005;70(5):346-351

4. Carvajal RO, Herrera CR, Porcile AR. Espectro fenotípico del síndrome de ovario poliquístico. Revista Chilena de Ginecología y Obstetricia 2010;75(2):124-132.

5. Diamanti-Kandarakis E; Argyrakopoulou G; Economou F; Kanaraki E; Koutsilieris M. Defects in insulin signaling pathways in ovarias steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). Journal of Steroid Biochemistry and Molecular Biology. 2008; 109: 242-246.

6. Fog SP, Madsbad ST, Nilas Ll. The insulln-resistant phenotype of polycystic ovary syndrome. Fertility and Sterility August 2010;3(94):1052-1058.

7. Gilkison C, Stuart CA. Assessment of patients with acanthosis nigricans skin lesions for hiperinsulinemia, insulin resistance and diabetes risk. Nurse Pract 1992; 17: 26-8.

8. Goodarzi M, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Practice and Research Clinical Endocrinology and Metabolism. 2006; 20 (2): 193-205.

9. Hernández VM, Rosas MH, Zárate A. Atención de la Resistencia a la insulina en el síndrome de ovarios poliquisticos. Ginecol Obstet Mex 2010;78(11):612-616

10. Hud JA Jr, Cohen JB. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128: 941-4.

11. Jones MR, Wilson S.G, Mullin B-H, Mead R- Watts G-F, Stuckey BGA- Polymorphism of the follistatin gene in polycystic ovary syndrome. Mollecular Human Reproduction.2007.

12. Katz AS, Goff DC, Feidman SR. Acanthosis nigricans in Obese patients: presentations and implications for prevention of atherosclerotic vascular disease. Dermatol Online J 2000; 6: 25-8.

13. Luque-Ramírez M; San Millán JL; Escobar-Morreale H. Genomic variants in polycystic ovary syndrome. Clinica Chimica Acta. 2006; 366: 14-26.

14. Poretsky L. Insulin resistance and hyperandrogenism: Update 1994. Endoc Rev 1994; 2: 26-35.

15. Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS. Distribution and characterization of insulin and insulin-like growth 1 receptors in normal human ovary. J Clin Endocrinol Metab. 1985; 61:355-62.

16. Poretsky L. Piper B. Insulin resistance hypersecretion of LH and dual defect hypothesis for the phatogenesis or polycystic ovary syndrome. Obstet Ginecology 1994: 84-613.

17. Rendon MI, Cruz PD Jr, Sonheimer RD, Bergstresser PR.Acanthosis Nigricans: A cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol 1989; 21: 461-9.

18. Varthakavi PK, Patel KL, Wadhwa SL, Shopkar U, Sengupta RA, Merchant PC, Mahtalia SD, Nihalani KD. A Study of insulin Resistance in Subjects with Acanthosis Nigricans. J Assoc Physicians India 2001; 49: 705-12.

19. Venkaten AM, Dunaif IF, Corbould AN. Insulin Resistance in Polycystíc Ovary Syndrome: Progress and Paradoxes. Endojournals. Org. 2011; Mayo.